SUN PHARMACEUTICAL Q2 PAT RISES 2.6% TO ₹3,118 CR

Pharma major Sun Pharmaceutical Industries on Wednesday reported a consolidated net profit of nearly Rs 3,118 crore in Q2FY26, registering a growth of 2.6% as against Rs 3,040 crore recorded in the year-ago period.

- FPJ News Service

The company’s total revenue from operations in Q2FY26 increased nearly 9% to Rs 14,478.31 crore from Rs 13,291.39 crore, year-on-year (y/y).

At the operating level, Sun Pharma reported EBITDA of Rs 4,527.1 crore during the September quarter, recording a 14.9% y/y. EBITDA margin was at 31.3%.

Kirti Ganorkar, managing director of the company, said, “India, emerging markets and the rest of the world led our growth for the period. US sales of innovative medicines have surpassed generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability.”